LYN-047

LYN-047 is an oral, once-weekly **extended-release rosuvastatin** capsule being developed by Lyndra Therapeutics for dyslipidemia and cardiovascular risk reduction through improved adherence to statin therapy. The product uses Lyndra's LYNX gastric-resident drug delivery platform to provide sustained release of rosuvastatin over approximately one week from a single capsule, with a 140 mg capsule intended to approximate a 20 mg daily rosuvastatin regimen. Pharmacologically, the active ingredient rosuvastatin is a small-molecule **HMG-CoA reductase inhibitor** that lowers low-density lipoprotein cholesterol by inhibiting hepatic cholesterol biosynthesis and upregulating LDL receptor-mediated clearance.

Other names

weekly rosuvastatin extended-release capsuleoral weekly rosuvastatin extended-release capsule